Abstract
Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have